PA
RNAC icon

Perceptive Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Perceptive Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-19,792
Closed -$6.05M – 146
2018
Q1 		$6.05M Sell
19,792
-1,298
-6% -$370K 0.17% 77
2017
Q4 		$6.21M Sell
21,090
-17,654
-46% -$7.71M 0.21% 72
2017
Q3 		$21.2M Buy
38,744
+12,166
+46% +$6.47M 0.81% 29
2017
Q2 		$15.8M Buy
26,578
+21,849
+462% +$9.65M 0.8% 35
2017
Q1 		$2.03M Hold
4,729
– – 0.12% 84
2016
Q4 		$2.43M Sell
4,729
-6,876
-59% -$4.02M 0.17% 77
2016
Q3 		$4.96M Sell
11,605
-3,395
-23% -$1.33M 0.32% 69
2016
Q2 		$6.3M Buy
+15,000
New +$6.3M 0.44% 50

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors's RNAC Position: Q2 2018 in Review

Perceptive Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2018, closing a stake of 19,792 shares — an estimated $6.05M sold.

Perceptive Advisors first reported a position in RNAC in Q2 2016 and held it in 8 quarters. The position peaked at $21.2M in Q3 2017. 57 funds tracked by Wall St. Rank hold RNAC as of Q2 2018.

  • Perceptive Advisors reported no remaining Cartesian Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Perceptive Advisors sold 19,792 Cartesian Therapeutics shares in Q2 2018, an estimated $6.05M.
  • Perceptive Advisors first reported a position in Cartesian Therapeutics in Q2 2016 and held it in 8 quarters.
  • Perceptive Advisors's Cartesian Therapeutics position peaked at $21.2M in Q3 2017.
  • 57 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.